$4.09+0.07 (+1.74%)
At close: Oct 2, 2026, 3:03 PM ET
Alpha Tau Medical Ltd · Financials
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+98.8%) and Capex step-up ($6.1M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼34.3%
−42.6
FY21→FY25CAGR —
Free cash flow ($M)▼48.7%
−32.8
capex stepped upCAGR —
Diluted EPS▼17.8%
−0.53
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+98.8%
40.5mn → 80.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$6.1M
▲171% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
| Line item | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 32,065.0 | 27,020.0 | 26,424.0 | 20,890.0 | 11,447.0 | ▲18.7% | +29.4% |
Selling, general & admin | 8,363.0 | 6,673.0 | 7,332.0 | 10,272.0 | 1,861.0 | ▲25.3% | +45.6% |
Total operating expenses | 42,288.0 | 36,042.0 | 35,680.0 | 32,136.0 | 13,790.0 | ▲17.3% | +32.3% |
Operating incomefeeds ROC rank | −42,288.0 | −36,042.0 | −35,680.0 | −32,136.0 | −13,790.0 | ▼17.3% | — |
Other income, net | −218.0 | 4,298.0 | 6,539.0 | −1,606.0 | −13,474.0 | — | — |
Pretax income | −42,506.0 | −31,744.0 | −29,141.0 | −33,742.0 | −27,264.0 | ▼33.9% | — |
Income tax | 121.0 | 6.0 | 16.0 | 20.0 | 7.0 | ▲1916.7% | +103.9% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −42,627.0 | −31,750.0 | −29,157.0 | −33,762.0 | −27,271.0 | ▼34.3% | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | −0.53 | −0.45 | −0.42 | −0.53 | −0.67b | ▼17.8% | — |
Diluted shares (mn) | 80.58 | 69.93 | 69.38 | 63.53 | 40.53 | ▲15.2% | +18.7% |
| Margins | |||||||
b Basic EPS. The company's diluted figure is not in our data feed for this period; its reported basic EPS agrees with net income to common shareholders over basic shares within 2%, so it is shown instead.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-09 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.